Novelix Pharma
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
Get instant stock alerts
- Share Price
- Financials
- Revenue mix
- Shareholdings
- Peers
- Forensics
Share Price
Coming soon
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
Financials
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
| (In Cr.) |
|---|
| (In Cr.) | ||||
|---|---|---|---|---|
|
This data is currently unavailable for this company. |
| (In %) |
|---|
| (In Cr.) |
|---|
| Financial Year (In Cr.) |
|---|
Revenue mix
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Forensics
Recent events
-
News
-
Corporate Actions
Novelix Pharmaceuticals' board has approved a preferential allotment of 1.2 million equity shares to 18 non-promoter investors to raise approximately ₹6.84 crores. The shares are priced at ₹57 each, representing a premium of ₹47 over the face value. The fresh capital is intended to bolster the company's financial position for general corporate purposes. The issuance remains subject to shareholder approval at an extraordinary general meeting scheduled for July 1, 2026.
Powered by Tijori
Novelix Pharmaceuticals' board has approved a preferential allotment of 1.2 million equity shares to 18 non-promoter investors to raise approximately ₹6.84 crores. The shares are priced at ₹57 each, representing a premium of ₹47 over the face value. The fresh capital is intended to bolster the company's financial position for general corporate purposes. The issuance remains subject to shareholder approval at an extraordinary general meeting scheduled for July 1, 2026.
Powered by Tijori
June 1 (Reuters) - Novelix Pharmaceuticals Ltd NOVE.BO:
TO CONSIDER PREFERENTIAL ISSUE OF SECURITIES
Source text: ID:nBSE5C93cZ
Further company coverage: NOVE.BO
(([email protected];))
June 1 (Reuters) - Novelix Pharmaceuticals Ltd NOVE.BO:
TO CONSIDER PREFERENTIAL ISSUE OF SECURITIES
Source text: ID:nBSE5C93cZ
Further company coverage: NOVE.BO
(([email protected];))
More Nano Cap Ideas
See similar 'Nano' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
- Business
- Financials
- Share Price
- Shareholdings
What does Novelix Pharma do?
Trimurthi Limited, a Public Limited Company based in Hyderabad, Telangana, is engaged in trading pharmaceuticals, related products, shares, and securities.
Who are the competitors of Novelix Pharma?
Novelix Pharma major competitors are ABans Enterprises, Parshva Enterprises, Chandrima Mercantile, Yantra Natural Res, Amrapali Industries, Swadeshi Inds & Leas, Emergent Ind. Solu.. Market Cap of Novelix Pharma is ₹190 Crs. While the median market cap of its peers are ₹194 Crs.
Is Novelix Pharma financially stable compared to its competitors?
Novelix Pharma seems to be less financially stable compared to its competitors. Altman Z score of Novelix Pharma is 3.83 and is ranked 8 out of its 8 competitors.
Does Novelix Pharma pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Novelix Pharma latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%
How has Novelix Pharma allocated its funds?
Companies resources are allocated to majorly unproductive assets like Accounts Receivable
How strong is Novelix Pharma balance sheet?
Balance sheet of Novelix Pharma is strong. It shouldn't have solvency or liquidity issues.
Is the profitablity of Novelix Pharma improving?
Yes, profit is increasing. The profit of Novelix Pharma is ₹2.56 Crs for TTM, ₹0.08 Crs for Mar 2025 and ₹0.01 Crs for Mar 2024.
Is the debt of Novelix Pharma increasing or decreasing?
The net debt of Novelix Pharma is decreasing. Latest net debt of Novelix Pharma is -₹1.35 Crs as of Mar-25. This is less than Mar-24 when it was -₹0.22 Crs.
Is Novelix Pharma stock expensive?
Yes, Novelix Pharma is expensive. Latest PE of Novelix Pharma is 74.96, while 3 year average PE is 47.08. Also latest EV/EBITDA of Novelix Pharma is 54.53 while 3yr average is 30.72.
Has the share price of Novelix Pharma grown faster than its competition?
Novelix Pharma has given better returns compared to its competitors. Novelix Pharma has grown at ~87.87% over the last 6yrs while peers have grown at a median rate of 31.67%
Is the promoter bullish about Novelix Pharma?
Promoters seem not to be bullish about the company and have been selling shares in the open market. Latest quarter promoter holding in Novelix Pharma is 49.43% and last quarter promoter holding is 51.98%
Are mutual funds buying/selling Novelix Pharma?
There is Insufficient data to gauge this.